Merck receives European Commission approval for ENFLONSIA (clesrovimab), a novel RSV preventive therapy for infants, designed to protect against lower respiratory tract disease during their first RSV season.
Infant Health | 20/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy